160 related articles for article (PubMed ID: 37486076)
21. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
[TBL] [Abstract][Full Text] [Related]
23. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
[TBL] [Abstract][Full Text] [Related]
24. Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations.
Park H; Shin HC; Yang H; Heo J; Ki CS; Kim HS; Kim JH; Hahn SY; Chung YJ; Kim SW; Chung JH; Oh YL; Kim TH
Mod Pathol; 2022 Feb; 35(2):186-192. PubMed ID: 34497362
[TBL] [Abstract][Full Text] [Related]
25. Effect of single-nucleotide polymorphism in TERT promoter on follicular thyroid tumor development.
Hirokawa T; Arimasu Y; Nakazato Y; Chiba T; Fujiwara M; Kamma H
Pathol Int; 2020 Apr; 70(4):210-216. PubMed ID: 31943533
[TBL] [Abstract][Full Text] [Related]
26. Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report.
Juhlin CC; Bränström R; Shabo I; Höög A
Int J Surg Pathol; 2019 May; 27(3):290-293. PubMed ID: 30370813
[TBL] [Abstract][Full Text] [Related]
27. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.
Proietti A; Sartori C; Macerola E; Borrelli N; Materazzi G; Vitti P; Basolo F
Virchows Arch; 2017 Dec; 471(6):769-773. PubMed ID: 28975450
[TBL] [Abstract][Full Text] [Related]
28. TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma.
Paulsson JO; Olander A; Haglund F; Zedenius J; Juhlin CC
Endocr Pathol; 2018 Dec; 29(4):380-383. PubMed ID: 30306386
[No Abstract] [Full Text] [Related]
29. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
30. Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status.
Park H; Heo J; Ki CS; Shin JH; Oh YL; Son YI; Kim JS; Kim SW; Chung JH; Kim TY; Kim TH; Kim JH
Ann Surg Oncol; 2023 May; 30(5):2916-2925. PubMed ID: 36637642
[TBL] [Abstract][Full Text] [Related]
31. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
[TBL] [Abstract][Full Text] [Related]
32. Advances in Detecting Low Prevalence Somatic
da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
[TBL] [Abstract][Full Text] [Related]
33. Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations.
Oishi N; Vuong HG; Mochizuki K; Kondo T
Endocr Pathol; 2020 Dec; 31(4):359-366. PubMed ID: 33058026
[TBL] [Abstract][Full Text] [Related]
34.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
35. BRAF and TERT promoter mutations: clinical application in thyroid cancer.
Chung JH
Endocr J; 2020 Jun; 67(6):577-584. PubMed ID: 32321884
[TBL] [Abstract][Full Text] [Related]
36. TERT Promoter Mutated Follicular Thyroid Carcinomas Exhibit a Distinct microRNA Expressional Profile with Potential Implications for Tumor Progression.
Paulsson JO; Zedenius J; Juhlin CC
Endocr Pathol; 2021 Dec; 32(4):513-516. PubMed ID: 34676499
[No Abstract] [Full Text] [Related]
37. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
38. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
39. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
[TBL] [Abstract][Full Text] [Related]
40. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
